Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Mini-Pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-Pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Ultra-Rare Bone Disease Therapy Gets FDA Panel Nod Despite Data Concerns

  • Post author:PacConAdmin
  • Post published:June 28, 2023
  • Post category:Drug Industry Daily

An FDA advisory committee voted 10 to 4 to recommend Ipsen Biopharmaceuticals’ palovarotene as an effective therapy for the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP), which causes tendons and…

Continue ReadingUltra-Rare Bone Disease Therapy Gets FDA Panel Nod Despite Data Concerns

EU Medical Associations Warn of Loss of Pediatric Devices Under EU MDR

  • Post author:PacConAdmin
  • Post published:June 28, 2023
  • Post category:Drug Industry Daily

The European Academy of Paediatrics (EAP) and 22 other European medical associations have written to the European Commission (EC) to warn that critical pediatric medical devices are being squeezed out…

Continue ReadingEU Medical Associations Warn of Loss of Pediatric Devices Under EU MDR

Compounders May Not Sell to Wholesalers to Qualify for 503B Exemption

  • Post author:PacConAdmin
  • Post published:June 28, 2023
  • Post category:Drug Industry Daily

The FDA’s interpretation and policies on exemption as well as prohibition of wholesaling of compounded drugs in section 503B of the Food, Drug & Cosmetic Act (FDC) are explained in…

Continue ReadingCompounders May Not Sell to Wholesalers to Qualify for 503B Exemption

Improving RWD Oncology Study Design is Goal of FDA QCARD Initiative

  • Post author:PacConAdmin
  • Post published:June 28, 2023
  • Post category:Drug Industry Daily

Receiving oncology study submissions that propose a too-wide range of types and formats of real world data (RWD) — along with a lack of basic elements of study design —…

Continue ReadingImproving RWD Oncology Study Design is Goal of FDA QCARD Initiative

Meeting Planner — Week of June 26, 2023

  • Post author:PacConAdmin
  • Post published:June 28, 2023
  • Post category:Drug Industry Daily

Upcoming events in the coming weeks include three FDA advisory committee meetings as well as webinars on the FDA's sterilization pilot and design control. Source: Drug Industry Daily

Continue ReadingMeeting Planner — Week of June 26, 2023

WHO and ICH to Collaborate on Unified Language for Drugs

  • Post author:PacConAdmin
  • Post published:June 27, 2023
  • Post category:Drug Industry Daily

WHO and the International Council for Harmonisation (ICH) plan to establish a unified language that streamlines global regulatory decision making on the safety and efficacy of drugs, while offering insights…

Continue ReadingWHO and ICH to Collaborate on Unified Language for Drugs

FDA Releases Draft Guidance on Submission of 3D Printed Orthopedic Implants

  • Post author:PacConAdmin
  • Post published:June 27, 2023
  • Post category:Drug Industry Daily

A new FDA draft guidance details what to include in a submission for regulatory approval of patient-matched guides used in pre-surgical planning for 3-D printed orthopedic implant systems such as…

Continue ReadingFDA Releases Draft Guidance on Submission of 3D Printed Orthopedic Implants

Use Quantitative Information for Consumer-Facing Promotion, FDA Guidance Says

  • Post author:PacConAdmin
  • Post published:June 27, 2023
  • Post category:Drug Industry Daily

When communicating about the efficacy and risks of prescription and OTC drugs directly to consumers, quantitative information “can improve consumers’ accuracy in estimating the drug’s benefits and risks” and should…

Continue ReadingUse Quantitative Information for Consumer-Facing Promotion, FDA Guidance Says

EMA Report Identifies Need to Anticipate, Hasten Agency-Led RWE Generation

  • Post author:PacConAdmin
  • Post published:June 27, 2023
  • Post category:Drug Industry Daily

There’s a need to tap into a greater array of data sources, identify and consider research questions earlier on, and speed up the generation of real-world evidence (RWE), according to…

Continue ReadingEMA Report Identifies Need to Anticipate, Hasten Agency-Led RWE Generation

Medical Advances Require Scientific, Regulatory, Social and Political Collaboration

  • Post author:PacConAdmin
  • Post published:June 27, 2023
  • Post category:Drug Industry Daily

I am good friends with a woman with Parkinson’s disease. When I see her, I feel grateful that this is the most exciting time in history for medical advancements. The…

Continue ReadingMedical Advances Require Scientific, Regulatory, Social and Political Collaboration
  • Go to the previous page
  • 1
  • …
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.